Leap Therapeutics (LPTX) Given News Sentiment Rating of 0.03

News articles about Leap Therapeutics (NASDAQ:LPTX) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Leap Therapeutics earned a news impact score of 0.03 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.4690423046981 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of NASDAQ:LPTX traded up $0.65 during trading hours on Friday, hitting $7.31. The company’s stock had a trading volume of 77,492 shares, compared to its average volume of 35,200. Leap Therapeutics has a 52 week low of $4.90 and a 52 week high of $10.25. The firm has a market cap of $96.57 million, a P/E ratio of -2.21 and a beta of -0.19.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). sell-side analysts expect that Leap Therapeutics will post -2.23 EPS for the current fiscal year.

Several research firms have recently commented on LPTX. ValuEngine upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Zacks Investment Research upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price target for the company in a report on Tuesday, July 17th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Featured Article: Marijuana Stocks

Insider Buying and Selling by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit